Search

Your search keyword '"Xu, Fei-Qi"' showing total 4 results
Start Over Author "Xu, Fei-Qi" Topic hepatocellular carcinoma
4 results on '"Xu, Fei-Qi"'

3. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.

Author

Ye, Tai-Wei, Wang, Dong-Dong, Lu, Wen-Feng, Xie, Ya-Ming, Xu, Fei-Qi, Fu, Tian-Wei, Zhang, Kang-Jun, Liu, Si-Yu, Xie, Gui-Lin, Cheng, Jian, Jiang, Kai, Xiao, Zun-Qiang, Yao, Wei-Feng, Shen, Guo-Liang, Liu, Jun-Wei, Huang, Dong-Sheng, Zhang, Cheng-Wu, and Liang, Lei

Subjects
CHEMOEMBOLIZATION, HEPATECTOMY, PROPENSITY score matching, PROGNOSIS, DISEASE relapse
Abstract

Although anatomical hepatectomy (AH) is widely used in the treatment of hepatocellular carcinoma (HCC), the prognosis is still unsatisfactory. The present study aimed to evaluate the survival benefit of adjuvant transcatheter arterial chemoembolization (TACE) for patients with HCC after AH. A total of 832 patients were stratified into with adjuvant TACE (443, 53.2%) and without adjuvant TACE group (389, 46.8%) AH. Propensity score matching (PSM) was performed to control for confounding factors, and multivariable Cox regression was performed to determine the independent risk factors. After PSM, the results showed that the adjuvant TACE group had better overall survival (OS) and recurrence-free survival (RFS). Among the patients with tumor recurrence, adjuvant TACE was associated with a high rate of early-stage tumor at recurrence, a lower recurrence rate around the frontal margin and extrahepatic metastases, and a higher rate of receiving curative treatment. Multivariable Cox regression analysis showed that adjuvant TACE was an independent prognostic factor for OS (HR 0.673, P = 0.001) and RFS (HR 0.650, P = 0.001). Patients with HCC after AH can benefit from postoperative adjuvant TACE. Therefore, adjuvant TACE should be considered for patients with a high risk of recurrence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Long noncoding RNA linc00462 promotes hepatocellular carcinoma progression

Author

YingCong Yu, Xizhou Lin, Jian-De Gong, Hong-Liang Li, YiRen Hu, Xu-Fei Qi, and Yi Zhang

Subjects
Male, 0301 basic medicine, Pathology, medicine.medical_specialty, Carcinoma, Hepatocellular, Carcinogenesis, Down-Regulation, Mice, Nude, Mice, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, Cell Line, Tumor, medicine, Animals, Humans, Clinical significance, neoplasms, PI3K/AKT/mTOR pathway, Pharmacology, Gene knockdown, Akt/PKB signaling pathway, business.industry, Liver Neoplasms, General Medicine, Middle Aged, medicine.disease, Phenotype, digestive system diseases, Long non-coding RNA, Up-Regulation, Gene Expression Regulation, Neoplastic, 030104 developmental biology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Disease Progression, Cancer research, Female, RNA, Long Noncoding, business, Signal Transduction
Abstract

Background Hepatocellular carcinoma (HCC) represents one of the most common malignancies worldwide. In two pubic long noncoding RNA (lncRNA) profiling studies of HCC, linc00462 was consistently upregulated. We analyzed the clinical significance and biological role of linc00462 in HCC. Methods We performed quantitative real-time PCR analysis to determine the levels of linc00462 in HCC tissues from 49 patients. Functional analysis was performed in cell lines and in an animal model to support clinical findings. Results Our data showed that linc00462 was significantly upregulated in HCC tissues compared with matched normal tissues. The knockdown of linc00462 in HCC cells resulted in a much less aggressive oncogenic phenotype, and linc00462 downregulation contribute to the inactivation of the PI3K/AKT signaling pathway. Conclusions linc00462 may be a potential therapeutic target in HCC.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results